Isoxazoline Derivative Preparation via Crystallization-Induced Dynamic Transformation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current caspase inhibitors, particularly those with the 3-amino-5-fluoro-4-oxopentanoic acid moiety, face challenges in effective preparation and stability, which affects their efficacy in treating various inflammatory and apoptotic conditions.
Innovation Solution
An isoxazoline derivative with a cyclic carboxylic acid hemiketal moiety is developed, utilizing a process involving crystallization-induced dynamic transformation to achieve high purity and stability, and is formulated into a pharmaceutical composition for treating inflammation and preventing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional preparation methods are used for caspase inhibitors, then the synthesis process is simpler, but the manufacturing precision and purity are insufficient
Solution Approach 1:
The patent introduces a preliminary protection step using acetal or ketal groups to protect the carbonyl functionality before performing condensation reactions. This preliminary action prevents unwanted side reactions and ensures high purity of the final product, resolving the contradiction between manufacturing precision and process complexity by adding a controlled protective step that simplifies subsequent reactions.
Solution Approach 2:
The patent employs specific parameter changes including controlled pH conditions (using buffers like phosphate or acetate at pH 4-6), temperature control (0-25°C), and stoichiometric ratios (1:1.1 to 1:2.0 of aldehyde to amine) to optimize the condensation reaction. These parameter changes enable high purity product formation while maintaining reasonable process complexity.
2Stability of the object's composition
If conventional caspase inhibitors are used, then the structure is simpler, but the stability is insufficient
Solution Approach 1:
The patent creates composite molecular structures by combining the 3-amino-5-fluoro-4-oxopentanoic acid moiety with cyclic acetal or ketal groups formed from diols. This composite structure integrates the caspase-inhibiting functionality with stabilizing cyclic protective groups, achieving both enhanced stability and maintained biological activity.
Solution Approach 2:
The patent converts the reactive carbonyl group, which can lead to instability and unwanted reactions, into a protected form using acetal or ketal chemistry. This transformation converts a potentially harmful reactive site into a stable protective structure that can be selectively deprotected later, achieving stability while preserving functionality.
3Productivity
If conventional preparation processes are used, then the process time is shorter, but the productivity is reduced due to low purity
Solution Approach 1:
The protective group strategy acts as a preliminary action that prevents the formation of impurities during the condensation reaction. By protecting the carbonyl group before reaction and selectively deprotecting afterward, the method avoids extensive purification steps, thereby improving effective yield without significant time loss.
Solution Approach 2:
The acetal or ketal protective groups serve as intermediary structures that facilitate the condensation reaction by preventing side reactions. These intermediates can be introduced and removed under mild conditions, reducing the need for time-consuming purification steps and improving overall productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The isoxazoline derivative exhibits strong caspase inhibition activity and improved stability, effectively treating conditions such as dementia, cerebral stroke, and hepatitis, with a stable crystalline form ensuring prolonged efficacy.
Implementation Method 1
crystallization-induced dynamic transformation
Data Source
AI summary
The present invention relates to an isoxazoline derivative having the cyclic carboxylic acid hemiketal moiety of formula (1) for use as caspase inhibitor, a process for preparing it, and a pharmaceutical composition comprising it.